Groupe d'Etude en Oncologie du Quebec

Title	Pelvic Nodes Ultra-Hypo Fractionated Versus Conventionally Fractionated IMRT With HDR Brachytherapy Boost in Prostate Cancer: A Collaborative Multi-institutional Non-inferiority Phase 3 Trial.
Protocole ID	PCS-XI
ClinicalTrials.gov ID	NCT05820633
Cancer Type(s)	Prostate
Phase	Phase III
Stage
Study Type	Clinical
Drug
Institution	CISSS DE L'OUTAOUAIS HOPITAL DE GATINEAU 909 Boulevard La Vérendrye, Gatineau, QC, J8P 7H2
City
Principal Investigator	Dr. Pierre-Yves McLaughlin
Coordinator	Céline Roy 819-966-6100 poste 3669
Status	Recruiting
Activation Date
Eligibility Criteria	Histopathologically confirmed adenocarcinoma of the prostate. All clinical stages with lymph node involvement risk needing pelvis RT. Stage Mx or M0. Unfavorable Intermediate, high or very high-risk disease according to NCCN guidelines. Having the ability to give free and informed consent.
Exclusion Criteria	Clinical stage M1. IPSS Score > 20 with alpha-blocking medication. Prior pelvic radiotherapy, History of active collagenosis (Lupus, Scleroderma, Dermatomyositis). Past history of Inflammatory Bowell Disease. Bilateral hip prosthesis.

Groupe d'étude en oncologie du Québec